We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
Read MoreHide Full Article
ImmuCell Corporation (ICCC - Free Report) shares traded near their 52-week high of $10.75, closing at $9.38 on April 17. The company is currently trading at a trailing 12-month enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA) multiple of 16.92X, representing a premium to the broader industry average of 10.4X. This year, ICCC has consistently commanded a higher valuation than its peers.
Image Source: Zacks Investment Research
Is the premium valuation justified? A closer look at ImmuCell’s operational progress, market-share gains and long-term growth prospects suggests that investors may be willing to pay up for quality and future earnings expansion.
One of the most important developments at ImmuCell has been its success in addressing manufacturing constraints that previously limited growth. In the first quarter of 2026, the average production output exceeded 450,000 manufacturing units per month, a substantial improvement from approximately 380,000 units in 2025, 344,000 units in 2024 and 252,000 units in 2023.
Management credited these gains to a series of operational enhancements, including improved coordination between sales and production planning, balanced workflows, reduced waste, selective overtime usage and targeted equipment investments to eliminate production bottlenecks.
The company is now preparing a significant expansion of its First Defense manufacturing capacity. Following the resolution of all disputes with a former contract manufacturer, ImmuCell received a net payment of $2 million, which management intends to invest in the expansion project. The planned upgrades include advanced processing flows, modern drying equipment and utilization of certain assets previously acquired for the discontinued Re-Tain program.
The expansion should improve product availability, support growing customer demand and provide a platform for sustained revenue growth and operating leverage over the long term.
Another encouraging development is ImmuCell’s ability to capture market share within the U.S. scours biologics market. While management estimates that the overall category expanded approximately 11% year over year in the first quarter of 2026, the company’s First Defense franchise significantly outperformed the broader market.
According to management, First Defense accounted for nearly 80% of the total category dollar expansion during the quarter, demonstrating strong customer adoption and increasing competitive strength. As a result, ImmuCell’s share of U.S. category spending increased from 29.1% in 2021 to 35.2% in the first quarter of 2026, while its share of animals treated rose from 15% to 18.1%.
These gains are particularly impressive, given that ImmuCell competes against much larger animal-health companies. Improved product availability, increased sales efforts and greater customer confidence have all contributed to the company’s success.
The strong performance also reflects the differentiated value proposition of First Defense. The product provides immediate protection against the three primary pathogens responsible for calf scours while delivering additional bioactive components derived from colostrum. This differentiation supports premium pricing and helps explain why the company’s share of category spending exceeds its share of animals treated.
Importantly, management estimates that 55% of calves still do not receive any biological scours treatment. This significant untapped market presents a substantial long-term growth opportunity for ImmuCell as awareness and adoption continue to increase.
Is ICCC Worth Its Premium Valuation?
The market has rewarded ImmuCell’s strong execution. Over the past year, ICCC shares have jumped 53.4%, significantly outperforming the sub-industry’s 27.9% decline and the S&P 500’s 29.4% advance.
Image Source: Zacks Investment Research
While the stock trades at a premium valuation relative to the industry, the higher multiple appears justified by the company’s accelerating production growth, expanding manufacturing capacity, increasing market share, improving margins and significant runway for future penetration within the calf-health market.
Investment Conclusion
Despite trading above the industry average valuation, ImmuCell’s strong fundamentals support the premium. The company is benefiting from rising production capacity, growing customer adoption of First Defense, expanding market share and a sizable long-term growth opportunity in an underpenetrated market.
Given its operational momentum, favorable industry dynamics and clear path toward continued revenue and earnings growth, investors should consider buying the ICCC stock even at current levels. The company’s growth prospects and improving business performance make the premium valuation appear warranted, positioning its shares for further upside over the long term.
View the Zacks #1 Rank List
Image: Bigstock
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell Corporation (ICCC - Free Report) shares traded near their 52-week high of $10.75, closing at $9.38 on April 17. The company is currently trading at a trailing 12-month enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA) multiple of 16.92X, representing a premium to the broader industry average of 10.4X. This year, ICCC has consistently commanded a higher valuation than its peers.
Is the premium valuation justified? A closer look at ImmuCell’s operational progress, market-share gains and long-term growth prospects suggests that investors may be willing to pay up for quality and future earnings expansion.
Manufacturing Improvements & Capacity Expansion Drive Growth Potential
One of the most important developments at ImmuCell has been its success in addressing manufacturing constraints that previously limited growth. In the first quarter of 2026, the average production output exceeded 450,000 manufacturing units per month, a substantial improvement from approximately 380,000 units in 2025, 344,000 units in 2024 and 252,000 units in 2023.
Management credited these gains to a series of operational enhancements, including improved coordination between sales and production planning, balanced workflows, reduced waste, selective overtime usage and targeted equipment investments to eliminate production bottlenecks.
The company is now preparing a significant expansion of its First Defense manufacturing capacity. Following the resolution of all disputes with a former contract manufacturer, ImmuCell received a net payment of $2 million, which management intends to invest in the expansion project. The planned upgrades include advanced processing flows, modern drying equipment and utilization of certain assets previously acquired for the discontinued Re-Tain program.
The expansion should improve product availability, support growing customer demand and provide a platform for sustained revenue growth and operating leverage over the long term.
Market-Share Gains Highlight Strong Customer Adoption
Another encouraging development is ImmuCell’s ability to capture market share within the U.S. scours biologics market. While management estimates that the overall category expanded approximately 11% year over year in the first quarter of 2026, the company’s First Defense franchise significantly outperformed the broader market.
According to management, First Defense accounted for nearly 80% of the total category dollar expansion during the quarter, demonstrating strong customer adoption and increasing competitive strength. As a result, ImmuCell’s share of U.S. category spending increased from 29.1% in 2021 to 35.2% in the first quarter of 2026, while its share of animals treated rose from 15% to 18.1%.
These gains are particularly impressive, given that ImmuCell competes against much larger animal-health companies. Improved product availability, increased sales efforts and greater customer confidence have all contributed to the company’s success.
The strong performance also reflects the differentiated value proposition of First Defense. The product provides immediate protection against the three primary pathogens responsible for calf scours while delivering additional bioactive components derived from colostrum. This differentiation supports premium pricing and helps explain why the company’s share of category spending exceeds its share of animals treated.
Importantly, management estimates that 55% of calves still do not receive any biological scours treatment. This significant untapped market presents a substantial long-term growth opportunity for ImmuCell as awareness and adoption continue to increase.
Is ICCC Worth Its Premium Valuation?
The market has rewarded ImmuCell’s strong execution. Over the past year, ICCC shares have jumped 53.4%, significantly outperforming the sub-industry’s 27.9% decline and the S&P 500’s 29.4% advance.
While the stock trades at a premium valuation relative to the industry, the higher multiple appears justified by the company’s accelerating production growth, expanding manufacturing capacity, increasing market share, improving margins and significant runway for future penetration within the calf-health market.
Investment Conclusion
Despite trading above the industry average valuation, ImmuCell’s strong fundamentals support the premium. The company is benefiting from rising production capacity, growing customer adoption of First Defense, expanding market share and a sizable long-term growth opportunity in an underpenetrated market.
Given its operational momentum, favorable industry dynamics and clear path toward continued revenue and earnings growth, investors should consider buying the ICCC stock even at current levels. The company’s growth prospects and improving business performance make the premium valuation appear warranted, positioning its shares for further upside over the long term.